[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"irritable-bowel-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:irritable-bowel-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,83,0,25,[9,47,71,99,128,154,175,194,220,253,276,304,328,353,380,401,425,446,469,499,525,548,568,586,616],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100513962","mechanisms-of-gulf-war-illness-100513962",false,"NCT05972291","Mechanisms of Gulf War Illness","Inclusion Criteria:\n\n1. Veterans 18-65 years old with GWI and chronic GI symptoms (abdominal pain, diarrhea, bloating) that started during their deployment in the Persian Gulf\n2. Veterans 18-65 years old with GWI and chronic GI symptoms (abdominal pain, diarrhea, bloating)\n3. increased intestinal permeability on the lactulose\u002Fmannitol permeability test (ratio \\>0.07)\n4. able and willing to cooperate with the study\n\nExclusion Criteria:\n\n1. current participation in another research protocol or unable to give informed consent\n2. women with a positive urine pregnancy test or breastfeeding\n3. history of inflammatory bowel disease, lactose intolerance and\u002For celiac sprue\n4. \\+ hydrogen breath test for bacterial overgrowth\n5. \\+ anti-endomysial antibody titer\n6. use of NSAIDs 2 weeks before or during the study\n7. known allergy to glutamine or whey protein\n8. abdominal surgery except for removal of gallbladder, uterus, or appendix \\>6 months prior to entry into the study\n9. Abnormal serum BUN and\u002For creatinine\n10. Mannitol recovery out of the normal range of 5-25 U\u002Fg\n11. history of kidney disease\n12. allergies to monosodium glutamate\n13. current use of anti-seizure medications","ALL","18 Years","65 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","Many veterans with Gulf War Illness developed chronic gastrointestinal symptoms during their deployment to the Persian Gulf. The pathophysiologic mechanisms of these chronic gastrointestinal symptoms are not well understood but cause significant morbidity in veterans. Our proposed studies will provide an innovative and novel treatment trial for chronic gastrointestinal symptoms in veterans with Gulf War Illness that were deployed into war zones. Given that there are currently no specific treatments for these disorders, and that current symptomatic approaches are far from ideal, proof of principle of our trial would be an extremely important advance as it would not only have a beneficial impact on the health of many thousands of our veterans, but also it would substantially reduce the many negative economic effects of this ailment on the VA Health Care System.",[27,28,29],"Gulf War Illness","Irritable Bowel Syndrome","Gastrointestinal Symptoms",[31,32,33],"gastrointestinal","irritable bowel syndrome","glutamine","RECRUITING","2026-08-17",{"date":37,"type":38},"2026-08-19","ACTUAL",{"date":40,"type":38},"2023-10-16",{"date":42,"type":21},"2027-09-30",{"name":44,"class":45},"VA Office of Research and Development","FED",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100638973","a-well-being-intervention-for-people-with-ibs-100638973","NCT07600047","A Well-Being Intervention for People With IBS","Inclusion Criteria:\n\n* Men and women currently diagnosed with Irritable Bowel Syndrome (IBS) by a healthcare provider.\n* Able to read and write in English.\n* Willing to complete questionnaires and participate in either the intervention or control group.\n* Capable of providing informed consent.\n* Must be a UW Health patient or referred through UW Digestive Health Center.\n\nExclusion Criteria:\n\n* Individuals with cognitive impairments or reading difficulties that would interfere with understanding study materials or completing assessments.\n* Individuals unable to provide informed consent.\n* Prior participation in a similar intervention study.\n* Non-English speakers (since study materials are in English)",{"count":54,"type":21},150,[24],"The purpose of this randomized behavioral clinical trial is to examine whether a well-being intervention can improve both psychological well-being and physical outcomes in adults with Irritable Bowel Syndrome (IBS). The study aims to assess whether this intervention decreases anger, anxiety, and depression; increases self-esteem, empathy, and hope; and improves quality of life indicators such as IBS symptom severity, sleep quality, fatigue, and diet. Participants can expect to be on study for up to 9 months.",[28],[59],"well being","NOT_YET_RECRUITING","2026-08-12",{"date":63,"type":38},"2026-08-13",{"date":65,"type":21},"2026-09",{"date":67,"type":21},"2027-08",{"name":69,"class":70},"University of Wisconsin, Madison","OTHER",{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":78,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100651413","calisthenics-versus-cycling-exercises-on-interleukin-6-and-quality-of-life-in-benha-university-students-with-irritable-bowel-syndrome-100651413","NCT07760298","Calisthenics Versus Cycling Exercises on Interleukin-6 and Quality of Life in Benha University Students With Irritable Bowel Syndrome","IBS","Inclusion Criteria:\n\n* females will be aged from 18 to 25 years old\n* diagnosis by Rome IV diagnostic criteria\n* BMI will be 18.5- 29.5 kg\\\\m2\n* (Moderate-severe) severity of IBS.\n\nExclusion Criteria:\n\n* organic gastro -intestinal disorders\n* thyroid dysfunctions\n* concurrent cardio vascular?\n* respiratory, renal, hepatic disorders\n* neurological\u002Fmusculoskeletal problems,\n* psychiatric disease,\n* hematological disease,\n* previous history of stomach or intestinal excision.\n* BMI will be \\>30 kg\\\\m2\n* Participating in any other ex progrm","FEMALE","25 Years",{"count":81,"type":21},60,[24],"this study will be conducted to compare between the effect of calisthenics versus cycling exercises on interleukin-6 and quality of life in Benha University students with irritable bowel syndrome.",[28],[86,87,88,89,90],"Calisthenics","Cycling Exercises","Interleukin-6","Quality of Life","Benha University Students With Irritable Bowel Syndrome","2026-08-07",{"date":61,"type":38},{"date":94,"type":21},"2026-08-20",{"date":96,"type":21},"2027-04-20",{"name":98,"class":70},"Cairo University",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":115,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100650607","liver-steatosis-and-fibrosis-in-non-celiac-wheat-sensitivity-patients-a-prospective-study-100650607","NCT07750535","Liver Steatosis and Fibrosis in Non-Celiac Wheat Sensitivity Patients: a Prospective Study","Prevalence and Risk Factors of Liver Steatosis and Fibrosis in Non-Celiac Wheat Sensitivity Patients: a Prospective Study","The inclusion\u002Fexclusion criteria used to select the study population have been previously validated in other retrospective studies. Additional exclusion criteria related to steatosis and other liver diseases and specifically required for this study were adopted.\n\nInclusion criteria for Non-Celiac Wheat Sensitivity (NCWS) patients\n\n* age \\>18 and \\\u003C65 years;\n* subjects with wheat-dependent symptoms, both gastrointestinal and extra-intestinal;\n* negativity of IgA and IgG anti-deamidated gliadin peptide (DPG) antibodies, immunoglobulin (Ig)A and IgG anti-tissue transglutaminase (tTG) antibodies, and anti-endomysial antibodies (EMA);\n* absence of duodenal villous atrophy, documented in all patients carrying the human leukocyte antigen (HLA) DQ2 and\u002For DQ8 haplotypes (therefore regardless of the negativity of celiac disease (CeD)-specific serum antibodies), evaluated when the patients had consumed a minimum of 100g of pasta and\u002For bread a day, for at least 45 days;\n* absence of IgE-mediated wheat allergy (WA): negative skin prick-test and\u002For specific serum IgE assay for wheat, gluten and gliadin);\n* resolution of symptoms on a strict standard elimination diet (i.e. extended oligoantigenic, excluding wheat, cow's milk, egg, tomato and chocolate and other foods self-reported by the patient as causing symptoms), followed for at least 4 weeks, and the recurrence of the same symptoms after double-blind placebo-controlled challenge (DBPCC) with wheat (for further details see below);\n* complete medical records;\n* duration of follow-up longer than 12 months after initial diagnosis, with at least 2 outpatient visits during the follow-up period.\n\nInclusion criteria for Irritable Bowel Syndrome\u002FFunctional Dyspepsia (IBS\u002FFD) and other functional gastrointestinal disorders unrelated to NCWS or other food allergies\u002Fintolerances patients\n\n* age \\>18 and \\\u003C65 years;\n* subjects diagnosed with IBS\u002FFD and other functional gastrointestinal disorders, according to the Rome IV classification, 1 who did not specifically report symptoms\u002Fsigns, whether gastrointestinal or extra-intestinal, following ingestion of wheat or other foods and who did not respond to gluten-free diet (GFD).\n\nInclusion criteria for Celiac Disease (CeD) patients\n\n* age \\>18 and \\\u003C65 years;\n* subjects with gastrointestinal and extra-intestinal wheat-dependent symptoms that meet the diagnostic criteria of CeD 2: positivity of anti-tTG IgA and\u002For IgG antibodies and evidence of villous atrophy, according to the Marsh-Oberhuber classification, demonstrated by histology on duodenal biopsy;\n* clinical response to the GFD: resolution of gastrointestinal and\u002For extra-intestinal symptoms.\n\nExclusion criteria for all the patients enrolled in the study\n\n* self-exclusion of wheat from the diet and refusal to reintroduce it for diagnostic purposes, before entering the study;\n* drug abuse;\n* treatment with steroids and\u002For non-steroidal anti-inflammatory drugs in the 2 weeks before duodenal biopsy;\n* pregnancy or breastfeeding;\n* diagnosis of chronic inflammatory bowel disease or other organic pathologies affecting the digestive system (e.g., wheat allergy, microscopic colitis, diverticulitis, segmental colitis associated with diverticulosis, etc.), neurological diseases, major psychiatric disorders, infectious diseases, immunological deficiencies, and impairments limiting physical activity;\n* incomplete medical records;\n* lack of clinical follow-up for at least 12 months after diagnosis with \\>2 outpatient visits during the follow-up period.\n\nAdditional exclusion criteria related to liver steatosis and other liver diseases\n\n* absence of abdominal ultrasound (US) imaging performed before diagnosis (i.e. before starting the wheat-free\u002Fgluten-free diet in NCWS and CeD patients, and before any lifestyle modifications and\u002For drug\u002Fprebiotic\u002Fprobiotic intake in IBS\u002FFD patients);\n* incomplete clinical records, lacking the data considered for the present study;\n* chronic alcohol intake (\\>30 g\u002Fday for men and \\>20 g\u002Fday for women);\n* chronic hepatotropic virus infections \\[hepatitis B virus (HBV) and hepatitis C virus (HCV)\\];\n* autoimmune liver diseases;\n* congenital metabolic liver diseases (e.g. alpha-1 antitrypsin deficiency, hemochromatosis, Wilson's disease, porphyria, other storage diseases, etc.);\n* chronic long-term treatment with drugs associated with both macrovesicular (glucocorticoids, estrogens, tamoxifen, amiodarone, methotrexate, and 5-fluorouracil) and microvesicular (glucocorticoids, valproic acid, tetracycline, and zidovudine) steatosis.",{"count":107,"type":21},250,"OBSERVATIONAL","Hypothesizing an intestinal barrier impairment as a common pathophysiological substrate of both Non Celiac Wheat Sensitivity (NCWS) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MAFLD), in a retrospective cohort study (data not yet published), demographic, clinical, laboratory and histology data of NCWS patients at the time of diagnosis, were analyzed and compared to control subjects with Irritable Bowel Syndrome\u002FFunctional Dyspepsia (IBS\u002FFD) and freshly diagnosed Celiac Disease (CeD). NCWS diagnosis was performed by a double-blind placebo-controlled wheat challenge. Steatosis was confirmed by ultrasound examination. Our retrospective data showed that the frequency of liver of steatosis was lower in NCWS than in IBS patients. In addition, it seems that pre-diagnosis avoidance of wheat in NCWS correlates with protection from steatosis. A subset of NCWS patients, recently exposed to wheat, with clinical features suggesting increased IP, seems to be predisposed to liver steatosis and fibrosis.\n\nTo validate the results of the retrospective study, the researchers planned the present prospective study, to analyze the prevalence of liver steatosis and fibrosis, evaluated by ultrasound (US) examination, FibroScan analysis \\[CAP (Controlled Attenuation Parameter) and LSM (Liver Stiffness Measurement) values\\], FIB-4 (Fibrosis-4) index, and NFS \\[Non-alcoholic fatty liver disease (NAFLD) Fibrosis Score\\], in patients with NCWS at the time of diagnosis, comparing them with two control populations of newly diagnosed IBS\u002FFD and CeD patients.",[111,112,28,113,114],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Non Celiac Wheat Sensitivity","Functional Dyspepsia","Celiac Disease",[116,117],"non-celiac wheat sensitivity","metabolic dysfunction-associated steatotic liver disease","2026-08-06",{"date":120,"type":38},"2026-08-11",{"date":122,"type":38},"2024-01-01",{"date":124,"type":21},"2030-12-31",{"name":126,"class":70},"University of Palermo",2,{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":153},"100634906","phase-2-a-study-of-brenipatide-ly3537031-in-participants-with-irritable-bowel-syndrome-constipation-ibs-c-100634906","NCT07545772","A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-C","RENEW-IBS-C","Inclusion Criteria:\n\n* Meets Rome IV criteria for irritable bowel syndrome-constipation (IBS-C) including having more than 25% bowel movements with Bristol Stool Form Scale (BSFS) Types 1 or 2 and less than 25% of bowel movements with BSFS Types 6 or 7\n* Based on the daily eDiary collection during the screening period:\n\n  * Have average of worst abdominal pain score of ≥3.0 on a 0-to-10-point scale during the 14 consecutive days prior to randomization\n\nExclusion Criteria:\n\n* Have a diagnosis of irritable bowel syndrome (IBS) with a subtype of diarrhea, mixed IBS, or unclassified IBS by the Rome IV criteria\n* Have a history of inflammatory or immune-mediated gastrointestinal disorders\n* Have a known clinically significant gastric emptying abnormality","75 Years",{"count":138,"type":21},342,[140],"PHASE2","The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo.\n\nThe study will last approximately 35 weeks.",[28,143],"Constipation","2026-08-05",{"date":118,"type":38},{"date":147,"type":38},"2026-04-29",{"date":149,"type":21},"2027-09",{"name":151,"class":152},"Eli Lilly and Company","INDUSTRY",70,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},"100634905","phase-2-a-study-of-brenipatide-ly3537031-in-participants-with-irritable-bowel-syndrome-diarrhea-ibs-d-100634905","NCT07545759","A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-D","RENEW-IBS-D","Inclusion Criteria:\n\n* Meet Rome IV criteria for IBS-D, which includes having greater than 25% of bowel movements with Bristol Stool Form Scale (BSFS) Types 6 or 7 and \\\u003C25% of bowel movements with BSFS Types 1 or 2\n* Based on the daily eDiary collection during the screening period:\n\n  * Have average of worst abdominal pain score of ≥3.0 on a 0-to-10-point scale during the 14 consecutive days prior to randomization\n  * Have at least 4 days per week with a maximum BSFS ≥5 AND with at least 2 days of the 4 days per week with a maximum BSFS ≥6 during the 14 consecutive days prior to randomization\n* Have had no major changes in diet in the 4 weeks prior to screening\n\nExclusion Criteria:\n\n* Have a diagnosis of IBS with a subtype of constipation, mixed IBS, or unclassified IBS by the Rome IV criteria\n* Have a history of inflammatory or immune-mediated gastrointestinal disorders\n* Have a known clinically significant gastric emptying abnormality",{"count":163,"type":21},531,[140],"The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo.\n\nThe study will last approximately 35 weeks.",[28,167],"Diarrhea",{"date":118,"type":38},{"date":170,"type":38},"2026-05-06",{"date":172,"type":21},"2027-11",{"name":151,"class":152},89,{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":46},"100302893","mucosal-and-microbiota-changes-during-acute-campylobacteriosis-100302893","NCT03223077","Mucosal and Microbiota Changes During Acute Campylobacteriosis","Inclusion Criteria:\n\n* No abdominal surgery (except appendectomy and cholecystectomy)\n* Stool culture or Polymerase chain reaction (PCR) positive enteritis with Campylobacter\n\nExclusion Criteria:\n\n* History of IBS, Irritable Bowel Disease (IBD) (Crohn's disease or ulcerative colitis), microscopic colitis or celiac disease.\n* History of gastroenteritis in six months prior to Campylobacter enteritis\n* Pregnancy","80 Years",{"count":54,"type":21},"Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to understand if changes in gut bacteria and gut mucosal lining during an acute infection can help identify individuals who might be at risk for developing problems in the future.",[28],[186],"Post infectious",{"date":91,"type":38},{"date":189,"type":38},"2014-10-31",{"date":191,"type":21},"2027-06",{"name":193,"class":70},"Mayo Clinic",{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":46},"100577660","single-center-exploratory-study-of-the-intestinal-microbiota-in-patients-treated-for-irritable-bowel-syndrome-with-predominant-constipation-and-methane-production-100577660","NCT06801184","Single-center Exploratory Study of the Intestinal Microbiota in Patients Treated for Irritable Bowel Syndrome With Predominant Constipation and Methane Production","Single-center Exploratory Study of the Intestinal Microbiota in Patients Suffering of Irritable Bowel Syndrome With Predominant Constipation and Methane Production: METHANOBIOTE","METHANOBIOTE","Inclusion Criteria:\n\n* Patient suffering from Irritable Bowel Syndrome (IBS) (abdominal pain for the past 6 months occurring on average at least 1 day per week in the last 3 months, with at least 2 of the following criteria: associated with defecation, associated with a change in stool frequency, associated with a change in stool consistency):\n\n  1. Predominant constipation type (IBS-C): Bristol Stool Scale 1-2 ≥ 25% of the time and Bristol Stool Scale 6-7 ≤ 25% of the time\n  2. Alternating diarrhea-constipation type (IBS-M): Bristol Stool Scale 1-2 25% of the time and Bristol Stool Scale 6-7 25% of the time\n  3. Unspecified type: absence of sufficient criteria to meet criteria for IBS-C, IBS-D, or IBS-M.\n* Patient exhibiting a high methane level (≥ 10 ppm) during a glucose breath test.\n* Aged ≥ 18 years at the time of study entry.\n* Patient not opposing participation in the study.\n\nExclusion Criteria:\n\n* Patient who has been treated with antibiotics or probiotics in the last 3 months prior to inclusion.\n* Patient suffering from diarrhea-predominant IBS (Bristol Stool Scale 6-7 ≥ 25% of the time and Bristol Stool Scale 1-2 ≤ 25% of the time).\n* Patient with a history of abdominal surgery other than appendectomy and cholecystectomy.\n* Patient with a history of celiac disease.\n* Patient with proven inflammatory bowel disease.\n* Patient with a history of colorectal cancer.\n* Patient with uncontrolled hypothyroidism.\n* Patient with uncontrolled diabetes.\n* Pregnant or breastfeeding women.\n* Patient deprived of liberty by a judicial or administrative decision.\n* Adult patient under legal protection (guardianship, curators).\n* Patient unable to discontinue proton pump inhibitor treatment during the study period",{"count":203,"type":21},40,"Irritable Bowel Syndrome (IBS), characterized by the Rome IV criteria, is a functional bowel disorder combining abdominal pain with changes in bowel habits and\u002For stool consistency. This condition is common, affecting 5% to 10% of the population in developed countries.\n\nThe etiology of IBS is multifactorial, involving intestinal motility disorders, visceral hypersensitivity, micro-inflammation of the intestinal mucosa, and dysbiosis. It has been demonstrated that the sub-category of IBS patients with constipation predominantly have increased amounts of Methanobrevibacter smithii, the most common methanogenic archaea found in the intestinal lumen, compared to other IBS patients.\n\nBreath tests can evaluate methane production by the intestinal microbiota, indirectly assessing the presence and quantity of methanogenic archaea. The acronym IMO (intestinal methanogen overgrowth) defines the association of digestive symptoms (notably bloating and constipation) with a high concentration of methane in exhaled gases (≥ 10 ppm).\n\nThe links between constipation, methane production, and fecal microbiota are uncertain, necessitating further studies that could lead to precise diagnostic and treatment recommendations.\n\nMain objective: Describe the initial composition of the fecal microbiota of constipated methano-producing IBS patients.\n\nSecondary objectives:\n\n2\\. Describe the initial composition of blood metabolites linked to the microbiota of constipated methano-producing IBS patients 3. Describe the evolution of the fecal microbiota and blood metabolites linked to the fecal microbiota during conventional therapeutic management (before and after) of constipated methano-producing IBS patients.\n\n4\\. Compare the composition of the fecal microbiota before and after conventional therapeutic management of responding IBS-C patients (-30% on the IBS-SSS symptom severity score) compared to non-responding patients.\n\n5\\. Evaluate the impact of Methanobrevicter smithii in the response to symptomatic treatment.\n\nExploratory observational single-center study (cohort follow-up) descriptive in patients with irritable bowel syndrome with constipation (IBS-C, IBS-m or IBS-U) with excessive methane production detected on a glucose breath test.\n\nPatients will be invited to participate once the results of the breath test are known.\n\nPlease note:\n\nIn the context of this study, only two microbiota samples and 4 additional tubes and one tube of blood will be added to the usual practice. All treatments will be prescribed as part of the care and are not conditioned by the research protocol.\n\nThe primary endpoint is the analysis of the initial composition (16S rRNA gene sequencing) of the fecal microbiota of constipated methano-producing IBS patients.\n\nThe study population consists of constipated IBS patients with excessive methane production seen in the digestive functional exploration department for a breath test prescribed as part of an external procedure or a day hospital session.\n\nA total of 40 patients will be included over 18 months, with a participation duration of 2 months +\u002F- 2months per subject.\n\nPatients with IBS constitute a heterogeneous population for whom only symptomatic treatment is currently offered with variable and unpredictable efficacy. Through this work, we seek to find new therapeutic axes to relieve or even treat their symptoms.",[28],[207,208,28,209,210],"gastroenterology","microbiota","constipation","methano-production","2026-07-24",{"date":213,"type":38},"2026-07-27",{"date":215,"type":38},"2025-02-10",{"date":217,"type":21},"2028-10-10",{"name":219,"class":70},"Hospices Civils de Lyon",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":251,"locationsCount":4},"100647991","enzymax-duobiotics-for-irritable-bowel-syndrome-100647991","NCT07716852","Enzymax DuoBiotics for Irritable Bowel Syndrome","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Efficacy and Safety of Enzymax DuoBiotics in Adults With Irritable Bowel Syndrome","ENZYMAX-IBS","Inclusion Criteria:\n\n* Adults aged 18 to 70 years\n* Diagnosis of irritable bowel syndrome according to the Rome IV criteria.\n* Presence of active irritable bowel syndrome symptoms at the time of enrollment.\n* Ability and willingness to provide written informed consent.\n* Ability and willingness to comply with the study procedures and the 12-week treatment period.\n\nExclusion Criteria:\n\n* Presence of an organic gastrointestinal disease.\n* Use of antibiotics or probiotics within 1 month before enrollment.\n* Recent clinically relevant changes in diet.\n* Severe comorbid medical conditions.\n* Inability or unwillingness to comply with the study protocol.\n* Known hypersensitivity to any component of Enzymax DuoBiotics or to dietary supplements of similar composition.\n* Any other condition that, in the investigator's judgment, may interfere with participation, study treatment, or interpretation of the results.","70 Years",{"count":230,"type":21},120,[24],"Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits in the absence of detectable structural abnormalities. Its pathophysiology is multifactorial and may involve alterations in the intestinal microbiota, impaired epithelial barrier function, low-grade immune activation, and disturbances in the digestion and fermentation of dietary nutrients.\n\nEnzymax DuoBiotics combines digestive enzymes with a synbiotic formulation in a capsule-in-capsule delivery system. The outer capsule contains digestive enzymes intended for release in the stomach, whereas the inner capsule contains Lactobacillus plantarum and fructooligosaccharides intended for release in the intestine. This formulation is designed to separate the enzymatic and synbiotic components and support their delivery to the intended gastrointestinal sites. The combined approach is intended to support macronutrient digestion while modulating the intestinal microbial environment.\n\nThis randomized, double-blind, placebo-controlled, parallel-group study will compare once-daily Enzymax DuoBiotics with placebo over a 12-week treatment period in adults with IBS. Participants will be allocated in a 1:1 ratio, and treatment effects over time will be evaluated using assessments performed during the treatment period. The primary statistical analysis will use linear mixed-effects models including treatment group, time, and the treatment group-by-time interaction. The primary analysis will follow the intention-to-treat principle and may be supplemented by a per-protocol analysis.",[28,234],"Irritable Bowel Syndrome (IBS)",[236,76,237,238,239,240,241,242,243,244],"Irritable bowel syndrome","Enzymax DuoBiotics","Dietary supplement","Synbiotic","Lactobacillus plantarum","Fructooligosaccharides","Digestive enzymes","Gastrointestinal symptoms","Gut microbiota","2026-07-22",{"date":247,"type":38},"2026-07-23",{"date":249,"type":21},"2026-09-30",{"date":42,"type":21},{"name":252,"class":70},"Gala Servicios Clinicos S.L.",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":16,"minAge":261,"maxAge":228,"enrollmentInfo":262,"targetDuration":4,"studyType":22,"phases":264,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":272,"leadSponsor":274,"locationsCount":4},"100646325","a-taiwan-adapted-self-management-program-for-adults-with-irritable-bowel-syndrome-100646325","NCT07693907","A Taiwan-Adapted Self-Management Program for Adults With Irritable Bowel Syndrome","A Pilot Randomized Controlled Trial of a Taiwanese Version of a Comprehensive Self-Management Program for Adults With Irritable Bowel Syndrome","CSM-T-IBS","Inclusion Criteria:Adults aged 20 to 70 years\n\n1. Meets Rome criteria for irritable bowel syndrome\n2. Has a healthcare provider diagnosis of irritable bowel syndrome\n3. Able to read and speak Mandarin\n4. Willing to provide informed consent and participate in study procedures\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding\n2. Poorly controlled mental health problems, including history of psychosis, bipolar disorder, drug or alcohol abuse or dependence, or suicide attempt within the past 2 years unless explained by significant loss\n3. Surgery or hospitalization within the past month\n4. Unable to complete study questionnaires or study procedures\n5. Unable to complete study questionnaires or study procedures -","20 Years",{"count":263,"type":21},54,[24],"This pilot randomized controlled trial will evaluate the feasibility, acceptability, and preliminary effects of a Taiwanese version of a comprehensive self-management program for adults with irritable bowel syndrome. Participants will be randomized to the self-management program or usual care. Outcomes will be assessed at baseline, immediately after the intervention, and three months after the intervention.",[28],[32],"2026-07-12",{"date":270,"type":38},"2026-07-15",{"date":270,"type":21},{"date":273,"type":21},"2028-07-25",{"name":275,"class":70},"National Defense Medical Center, Taiwan",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":46},"100570402","the-mechanism-underlying-the-analgesic-effect-of-the-music-of-ibs-pain-100570402","NCT06706778","The Mechanism Underlying the Analgesic Effect of the Music of IBS Pain","Impacts of Music-based Intervention on Pain in Individuals With Irritable Bowel Syndrome (IBS): A Mechanistic Pilot Study","Inclusion Criteria:\n\n* aged between 18 and 50 years old,\n* can speak and read English,\n* having a confirmed diagnosis of IBS from a healthcare provider,\n* having experienced moderate pain (≥3 out of 10 on a numeric rating scale) at least four days a week for the past three months,\n* be willing to participate in a 4-week intervention and attend two lab visits, and\n* having daily access to an internet-enabled device for MBI.\n\nExclusion Criteria:\n\n* having a severe psychiatric disorder requiring inpatient treatment in the past six months,\n* regularly using opioids or illicit substances, or have used probiotics or antibiotics within two weeks prior to enrollment,\n* having celiac disease, inflammatory bowel disease, or a history of major gastrointestinal surgery,\n* concurrently participate in another IBS-related intervention study.","50 Years",{"count":285,"type":21},30,[24],"The proposed pilot study aims to assess the underlying mechanisms of the MBI on IBS pain and the feasibility of using novel technology in the outcome measurements. The specific aims of this pilot mechanistic clinical trial are to:\n\n1. . identify the mechanisms underlying the impact of MBI on IBS-related pain, stress responses, quantitative pain sensitivity, and gut microbiome profiles.\n2. . evaluate the technological feasibility of using a wearable abdominal sensor belt and smartwatch system in measuring MBI impacts on pain in home settings.\n\nResearchers will conduct a one-arm pre- and post-music intervention among patients with Irritable Bowel Syndrome, collect the IBS pain mechanistic biobehavioral markers, and analyze the underlying pathways of the music analgesic effect.\n\nParticipants will be asked to:\n\n1. . engage in a 4-week intervention of 20 minutes, both during the day and at night, for at least five days per week.\n2. . have two one-hour lab visits",[289,28],"Abdominal Pain\u002F Discomfort",[291,292,293,294,28],"abdominal pain","Music","Brain-gut axis","Stress","2026-06-30",{"date":297,"type":38},"2026-07-02",{"date":299,"type":21},"2026-08",{"date":301,"type":21},"2027-03",{"name":303,"class":70},"Yale University",{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":228,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":313,"conditions":314,"keywords":316,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":46},"100547825","brachyspira-and-intestinal-allergy-like-immune-reactions-in-patients-with-irritable-bowel-syndrome-ibs-100547825","NCT06413004","Brachyspira and Intestinal Allergy-like Immune Reactions in Patients With Irritable Bowel Syndrome (IBS)","Inclusion Criteria:\n\n* Patients with IBS diagnosis according to their treating physician (ROME IV).\n* Association between intake of food and GI symptoms.\n* Witnessed written informed consent prior to any study procedures.\n* Patients who are capable to understand the study and the questionnaires, and to comply with the study requirements.\n\nExclusion Criteria:\n\n* Patients with relevant concurrent organic GI disease (inflammatory bowel disease, abdominal cancer), or a major disease such as diabetes, uncontrolled thyroid disease, heart disease, kidney disease, liver disease, and active malignant disease (not those that were in remission at least 5 years).\n* Patients with a history of bowel surgery (not appendectomy or cholecystectomy) that affects GI motility.\n* Patients with systemic food allergy as evidenced by positive allergy tests (blood, prick test).\n* Clinical history of severe allergic reactions.\n* Patients with concurrent major confounding condition(s) based on the clinician's judgement, e.g. DOMINANT psychiatric disorder, vital depression, alcohol or substance abuse in the last 2 year.\n* Female patients who are pregnant or lactating (females of fertile age are requested to use a safe contraceptive) at the time of inclusion.\n* Patients who use or used new medications that affect the GI functioning within 1 month before the start of the study.",{"count":311,"type":21},200,[24],"The aim of this study is to define local immune responses in the GI tract to food antigens in IBS patients, with and without Brachyspira infection, using advanced imaging. We hypothesize that Brachyspira infection can cause IBS symptoms by inducing loss of oral tolerance to dietary antigens through development of food-specific intestinal immune reactions and subsequent development of visceral hypersensitivity.\n\nDuring this study, the investigators will perform confocal laser endomiscroscopy (CLE) and\u002For colonoscopic antigen provocation test (COLAP) to test to which food items the participants react to. Furthermore, the investigators will perform rectal barostat examination and a sigmoidoscopy without laxatives. The investigators will collect biological samples and the participants will complete several questionnaires.",[28,315],"Food Sensitivity",[28,315,317,318],"Confocal Laser Endomicroscopy","Colonoscopic Antigen Provocation Test","2026-06-24",{"date":321,"type":38},"2026-06-29",{"date":323,"type":38},"2022-08-03",{"date":325,"type":21},"2027-12-01",{"name":327,"class":70},"Magnus Simrén",{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":343,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":46},"100645017","a-pilot-study-using-gut-directed-hypnotherapy-for-hospitalized-patients-100645017","NCT07676136","A Pilot Study Using Gut-Directed Hypnotherapy for Hospitalized Patients","Inclusion Criteria:\n\n* Adults admitted to the GI inpatient service with expected length of stay \\>24 hours\n* Prior diagnosis of a disorder of gut-brain interaction, esophageal disorder, or inflammatory bowel disease\n* Reason for hospitalization related to symptom management for exacerbation of visceral pain and\u002For nausea.\n\nExclusion Criteria:\n\n* Currently using hypnosis\n* severe developmental delay or cognitive impairment\n* serious mental illness (i.e. psychosis or dissociation)\n* hearing impairment\n* Non-English speaking\n* enrolled in another trial for GI symptom management\n* admitted for GI procedure",{"count":335,"type":21},26,[24],"The purpose of the study is to compare the effectiveness of recorded gut-directed hypnosis to an educational recording in people with chronic problems in their gastrointestinal (GI) system. Patients who are hospitalized at Stanford Hospital for worsening pain and\u002For nausea will be considered for enrollment.",[339,340,28,341,342],"Disorders of Gut-brain Interaction","Inflammatory Bowel Disease (IBD)","Abdominal Pain","Esophageal Disease",[344],"hypnosis","2026-06-23",{"date":295,"type":38},{"date":348,"type":21},"2026-07",{"date":350,"type":21},"2028-07",{"name":352,"class":70},"Stanford University",{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":181,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":363,"briefSummary":364,"conditions":365,"keywords":366,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":379},"100632877","phase-2-a-study-to-investigate-abdominal-symptoms-with-camlipixant-compared-with-placebo-in-adults-with-irritable-bowel-syndrome---diarrhea-ibs-d-and-irritable-bowel-syndrome---mixed-ibs-m-100632877","NCT07519395","A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)","BALANCE - A Two-part, 26-week, Randomized, Double-Blind, Dose-rAnging, pLAcebo-coNtrolled, Phase 2b Study to Evaluate the effiCacy and safEty of Camlipixant in Adults With IBS-D and IBS-M","BALANCE","Inclusion Criteria:\n\n* Male or female aged 18 to 80 years inclusive, at the time of signing the Informed consent form (ICF).\n* Diagnosis of IBS-D or IBS-M according to the Rome IV criteria at screening\n* Moderate or severe irritable bowel syndrome (IBS) based on Irritable bowel syndrome Severity Scoring System (IBS SSS) at screening visit\n* Weekly API score \\>=4.0 in each week of the run-in period\n* IBS-D: at least one stool with BSFS Type 6 or 7 consistency on at least 2 days in each week of the run-in period\n* IBS-M: an average of 2 days per week with abnormal bowel movements (BSFS Type 1, 2, 6, or 7) during the run-in period, and greater than (\\>)25% of abnormal bowel movements must be Type 6 or 7 and \\>25% Type 1 or 2\n\nExclusion Criteria:\n\n* Diagnosis of Irritable bowel syndrome - constipation (IBS-C) or Irritable bowel syndrome - unclassified (IBS-U)\n* History or presence of inflammatory or immune-mediated Gastrointestinal (GI) disorders e.g. inflammatory bowel disease, microscopic colitis, or celiac disease\n* History or presence of GI infection (confirmed with stool culture) within 3 months prior to screening\n* History or presence of bile salt diarrhea\n* History of a primary psychiatric diagnosis that the Investigator considers may interfere with study assessments (e.g., schizophrenia, schizoaffective disorder, major depression, anxiety, panic attacks or bipolar disorder) OR Hospital Anxiety and Depression Scale (HADS) score of \\>10 at screening.\n* Prior use of more than two of the following therapies or classes of therapy for the management of IBS:\n\n  * Antidepressants or neuromodulators (e.g., Tricyclic antidepressant \\[TCAs\\], Selective serotonin reuptake inhibitor \\[SSRIs\\], gabapentinoids)\n  * Antibiotics (e.g., rifaximin, neomycin)\n  * 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (e.g., alosetron, ramosetron, ondansetron)\n  * Mu-opioid receptor agonists (e.g., eluxadoline)\n  * Secretagogues (e.g., linaclotide, lubiprostone, plecanatide, tenapanor)\n  * 5-hydroxytryptamine 4 (5-HT4) receptor agonists (e.g., tegaserod)\n* Abnormal thyroid function tests less than (\\\u003C) Lower limit of normal (LLN) or greater than (\\>) upper limit of normal (ULN) confirmed at screening with Thyroid stimulating hormone (TSH)\n* Positive celiac serology\n* Elevated fecal calprotectin levels\n* QT interval corrected using Fridericia's formula (QTcF) \\>450 millisecond (msec) or QTcF \\>480 msec for participants with bundle branch block using the Fridericia's corrected QT interval.\n* Clinically significant abnormal laboratory tests at screening, after one repeat laboratory test if allowed by the Medical Monitor, including the following:\n\n  * Alanine aminotransferase (ALT) \\>2\\*ULN\n  * Total Bilirubin \\>1.5\\*ULN\n  * Aspartate aminotransferase (AST) \\>2\\*ULN\n* Current or chronic history of liver disease (Child-Pugh class A, B, or C) or biliary abnormalities (with the exception of asymptomatic gallstones). Participants with known or suspected Gilbert's Syndrome are not permissible.",{"count":362,"type":21},420,[140],"This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts. After the first part, some participants will be randomly chosen again to either get a higher dose or stop the drug.",[28],[367,368,369,370],"Camlipixant","Irritable bowel syndrome - Mixed","Irritable bowel syndrome - Diarrhea","Dose Ranging",{"date":372,"type":38},"2026-06-25",{"date":374,"type":38},"2026-04-08",{"date":376,"type":21},"2027-07-13",{"name":378,"class":152},"GlaxoSmithKline",110,{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":387,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":46},"100630999","defining-objective-markers-of-compliance-for-dietary-therapies-in-ibs-100630999","NCT07494968","Defining Objective Markers of Compliance for Dietary Therapies in IBS","Defining Objective Markers of Compliance for Dietary Therapies in Irritable Bowel Syndrome (IBS) Using a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients with IBS ( including diarrhea, mixed or constipation type) and without unexplained alarm features (rectal bleeding, weight loss, nocturnal pain, nocturnal diarrhea). In presence of alarm symptoms, if they have had evaluation with colonoscopy or fecal calprotectin or serum C-reactive protein (CRP) since onset of alarm symptoms with normal results, they will be included.\n2. Aged 18-65 years at the time of screening\n3. IBS-SSS of at least 175 at baseline\n\nExclusion Criteria:\n\n1. Subjects adhering to a dietary treatment such as the low-fat diet, low FODMAP diet, or gluten-free diet, within the past 6 months. Those who are lactose intolerant will not be excluded from the study and will be allowed to limit lactose intake as previously.\n2. Subjects who are predicted to make changes to their baseline IBS medication(s), over-the-counter (OTC) therapy, exercise, diet (beyond what is advised), or initiate\u002Fmake changes to other complementary therapy that could affect IBS symptoms (e.g. yoga, acupuncture, etc.) during the four weeks study period.\n3. Subjects with a known history of celiac disease, inflammatory bowel disease or microscopic colitis\n4. Subjects with a history of an eating disorder requiring medical or behavioral treatment within the past 10 years.\n5. BMI \\\u003C 18.5\n6. Subjects with prior small bowel or colonic surgery (other than appendectomy or cholecystectomy).\n7. History of appendectomy or cholecystectomy in the last 6 months.\n8. Oral antibiotic use in the past 3 months\n9. Any planned significant changes in dietary or exercise regimen within 30 days prior to Screening or during the study.\n10. Currently pregnant or breastfeeding.",{"count":388,"type":21},94,[24],"This research will investigate if a specific marker in your stool or urine can be used to track changes in your carbohydrate intake including fructo-oligosaccharide and mannitol intake",[28],"2026-06-18",{"date":394,"type":38},"2026-06-22",{"date":396,"type":38},"2026-05-11",{"date":398,"type":21},"2027-12",{"name":400,"class":70},"University of Michigan",{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":22,"phases":410,"briefSummary":411,"conditions":412,"keywords":413,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":418,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":46},"100582653","well-being-in-ibs-strengths-and-happiness-wish-20-100582653","NCT06866106","Well-being in IBS: Strengths and Happiness (WISH) 2.0","The WISH Intervention for IBS: Feasibility, Preliminary Effects, and Candidate Gut-Brain Mechanisms","Inclusion Criteria:\n\n* IBS Diagnosis: Adult patients with an IBS diagnosis meeting standardized Rome IV diagnostic criteria.\n* Language and communication: English fluency and access to a phone.\n\nExclusion Criteria:\n\n* Presence of inflammatory bowel disease or other structural\u002Fbiochemical primary gastrointestinal illness that better explains IBS-like symptoms: As reported by the patient, their physician, and\u002For documented in the medical record.\n* Severe psychiatric illness: Current manic episode, psychosis, or active substance use disorder diagnosed via the Mini International Neuropsychiatric Interview (MINI) or Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders (DIAMOND).\n* Cognitive impairment: Assessed using a six-item cognitive screen developed for research.\n* Presence of atrial fibrillation or a cardiac pacemaker, or daily use of beta blocking medication: As reported by the patient and\u002For documented in the medical record.\n* Plans to start or participate in another new behavioral health intervention or psychotherapy during the study period.",{"count":409,"type":21},50,[24],"The purpose of this study is to examine the feasibility, acceptability, preliminary effects, and candidate gut-brain mechanisms of an optimized positive psychology (PP) intervention for patients with irritable bowel syndrome (IBS), entitled \"WISH,\" compared to an educational control intervention.",[28],[32,414,415,416,417],"brain-gut behavior therapy","behavioral health intervention","psychological intervention","psychotherapy",{"date":394,"type":38},{"date":420,"type":38},"2025-10-30",{"date":422,"type":21},"2028-08",{"name":424,"class":70},"Massachusetts General Hospital",{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":432,"sex":16,"minAge":17,"maxAge":228,"enrollmentInfo":433,"targetDuration":4,"studyType":22,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":442,"leadSponsor":444,"locationsCount":46},"100513964","the-stool-microbiome-of-treated-and-untreated-ibs-irritable-bowel-syndrome-patients-100513964","NCT05972317","The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients","Generating a Stool Microbiome-based Diagnostic for IBS (Irritable Bowel Syndrome) Patients in Low-FODMAP Treated and Untreated IBS Patients","Inclusion Criteria:\n\n* Male and Female\n* Age - 18-70\n\nExclusion Criteria:\n\n* Consumption of antibiotics 2 months prior to the first day of the experiment.\n* Consumption of probiotic supplements 1 month prior to the first day of the experiment.\n* Type 1 or type 2 diabetes diagnosis.\n* Pregnancy, fertility treatments, breastfeeding 3 months prior to the first day of the study.\n* Chronic disease - to the discretion of the study doctor.\n* Cancer and recent anticancer treatment.\n* Psychiatric disorders - to the discretion of the study doctor.\n* IBD (inflammatory bowel diseases).\n* Alcohol or substance abuse.\n* BMI \\> 35.",true,{"count":434,"type":21},100,[24],"Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease. However, the characteristics and functions of these metabolites remain unknown to date. The two main mechanisms invoking IBS development and flares include 1) an increase in luminal water content due to malabsorption of small molecules and 2) incrementation of colon gas production generated by the fermentation of small molecules by gut bacteria.Yet to date, a person-specific elucidation of the specific small molecules and bacteria driving IBS, and their downstream effects on the human gut epithelium remain unknown.\n\nOver the past years, it became evident that dietary regimes, and their interactions with the intestinal microbiome, are at the center of IBS symptom generation and alleviation. The most widely used dietary intervention is a highly restrictive diet, the low-Fermentable Oligo-saccharides Di-saccharides Mono-saccharides And Polyols (FODMAP) diet, based on avoidance of multiple food items that contain available fermentable molecules.\n\nThe low-FODMAP diet remains an effective line of treatment for IBS patients, yet due to its complexity and unhealthy nature, it remains a last line of treatment and fails to impact the majority of IBS patients.",[28],"2026-06-09",{"date":440,"type":38},"2026-06-11",{"date":396,"type":38},{"date":443,"type":21},"2029-11",{"name":445,"class":70},"Weizmann Institute of Science",{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":16,"minAge":454,"maxAge":455,"enrollmentInfo":456,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":460,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":467,"locationsCount":46},"100565269","phase-2-psyllium-in-pediatric-ibs-100565269","NCT06639984","Psyllium in Pediatric IBS","Assessing Psyllium Given With Meals for Fructan Sensitivity in Children With Irritable Bowel Syndrome","Psyllium","Inclusion Criteria:\n\n* Children between the ages of 12-17 years meeting pediatric Rome IV criteria for IBS\n\nExclusion Criteria:\n\n* Children who have had previous bowel surgery, have documented GI disorders (e.g., ulcerative colitis), or a serious chronic medical condition (e.g., diabetes)\n* weight and\u002For height are \\> or \\< 2 SD for age\n* have chronic conditions with GI symptoms (e.g., cystic fibrosis)\n* have been on antibiotics or probiotics within 3 months (because of potential alterations to the GI microbiome0\n* girls who are pregnant (tested with urine beta-human chorionic gonadotropin at the initial visit)","12 Years","17 Years",{"count":379,"type":21},[140],"The goal of this clinical trial is to learn if a fiber (psyllium) can change the way bacteria use fructans (a type of sugar) and whether psyllium can help decrease childhood irritable bowel syndrome (IBS) symptoms when eating fructans. The main questions it aims to answer are:\n\nAim 1: The effect of psyllium at two doses given with a fructan meal on microbial fructan fermentation (intracolonic pH; H2 gas production; gut microbiome composition; fecal short-chain fatty acids, lactate, glycomics).\n\nAim 2: Determine the impact of psyllium given with a fructan meal on fructan-induced GI symptoms.\n\nParticipants will first be asked to eat a specific diet over two three-day periods to determine if fructans worsen their IBS symptoms. Those with worsening symptoms with fructans will be asked to participate in the second part of the study. This includes two weeks of baseline (no change in diet) and two weeks of eating a specific diet with fructans with either psyllium or glucose. Participants will be asked to complete pain and stool diaries, submit stool specimens, swallow a pill to capture gut acid levels, and give breath samples.",[28],[341],"2026-05-21",{"date":463,"type":38},"2026-05-26",{"date":465,"type":38},"2025-02-20",{"date":42,"type":21},{"name":468,"class":70},"Dr Bruno Chumpitazi, M.D.",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":22,"phases":477,"briefSummary":479,"conditions":480,"keywords":488,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":497,"locationsCount":46},"100536954","phase-4-evaluation-of-efficacy-of-skl-pro-powder-on-symptoms-of-irritable-bowel-syndrome-100536954","NCT06271538","Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome","A Randomized Double-Blind Placebo-controlled Clinical Trial on the Efficacy of Skål Pro (Lactobacillus Plantarum 299 and Galacto-oligosaccharides) in Improving Severity of Symptoms, Stool Forms, Quality of Life and Psychological Dysfunction in Patients With Irritable Bowel Syndrome (IBS)","Inclusion Criteria:\n\n* IBS diagnosed using the Rome IV criteria\n* Age above 18 years old and any gender\n* Any subtypes of IBS (diarrhea, constipation or mixed)\n\nExclusion Criteria:\n\n* Presence of red flag symptoms (weight loss, anemia, night symptoms, abdominal mass, strong family history of cancer)\n* Was prescribed antibiotic (s) within the past one month\n* Medical conditions that contraindicate probiotic use including severe sepsis and pregnancy\n* Presence of bowel malignancy\n* Diagnosis of bowel infection within the past one month\n* Previous abdominal surgeries\n* Patients with overt psychiatric illnesses including schizophrenia and manic disorders\n* A history of allergy to probiotic\n* Was prescribed probiotic (s) within the past one month\n* Was previously prescribed probiotic Skal Pro™ (LP299V™)",{"count":81,"type":21},[478],"PHASE4","The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.",[28,481,482,483,484,485,486,487],"Gastrointestinal Diseases","Colonic Diseases, Functional","Intestinal Disease","Digestive System Disease","Pathologic Processes","Colonic Disease","Disease",[489,490,491],"probiotic","Lactobacillus plantarum 299v","randomized controlled study",{"date":493,"type":38},"2026-05-12",{"date":495,"type":38},"2024-10-17",{"date":295,"type":21},{"name":498,"class":152},"EP Plus Group Sdn Bhd",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":228,"enrollmentInfo":507,"targetDuration":4,"studyType":22,"phases":509,"briefSummary":510,"conditions":511,"keywords":516,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":46},"100639308","repeated-transcranial-magnetic-stimulation-for-the-treatment-of-diarrhea-predominant-irritable-bowel-syndrome-a-randomized-clinical-trial-100639308","NCT07581756","Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial","Repeated Transcranial Magnetic Stimulation (rTMS) for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial","rTMS","Inclusion Criteria:\n\nEligible participants had to be between 18- 60 years of age and fulfill the Rome IV criteria for IBS-D. Specifically, patients must have experienced recurrent abdominal pain at least one day per week in the last three months, with symptom onset at least six months prior to diagnosis, associated with defecation or a change in the frequency or form (appearance) of stool. More than 25% of stool episodes be classified as Bristol Stool Form Scale (BSFS) type 6 or 7, and fewer than 25% as type 1 or 2. In addition, patients were required to exhibit moderate to severe symptoms, defined as an Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) score greater than 175 (on a 500-point scale). Dietary preferences of all participants included non vegetarian options and participants maintain stable dietary habits for at least one month prior to randomization. Moreover, patients aged over 50 were required to provide documentation of a normal colonoscopy performed within the preceding three years.\n\nExclusion Criteria:\n\nThe exclusion criteria included a completion rate of daily diaries of less than 50% during the screening period, a history of organic gastrointestinal disease, such as inflammatory bowel disease, a history of surgical resection of the GI tract or cholecystectomy, a recent diagnosis of Helicobacter pylori infection within the past 2 years, a history of gluten or lactose intolerance, a history of malignancy, or a history of neurological or psychiatric conditions. Additionally, individuals with severe systemic diseases, including uncontrolled diabetes mellitus, hyperthyroidism, or severe hepatic, renal, or cardiac insufficiency, were excluded. The use of probiotic or prebiotic supplements, antibiotics (including rifaximin), prokinetic or antidiarrheal agents, tricyclic antidepressants, or immunosuppressive therapies was not permitted within 4 wk prior to screening. Prohibited conditions during the study period included pregnancy, lactation, or being within 12 months postpartum. Lastly, participants with severe needle phobia, metal allergies, implanted cardiac pacemakers, or a known allergic diathesis were excluded. All participants provided their voluntary, written, informed consent prior to their inclusion.",{"count":508,"type":21},46,[24],"Objectives: This study aims to evaluate the clinical efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore the potential underlying mechanisms by which rTMS alleviates clinical symptoms in IBS-D patients.\n\nDesign: This is a clinical trial that uses clinical symptom scales to assess the therapeutic effect of rTMS on IBS-D patients. Meanwhile, gut microbiota and metabolite profiling, as well as the methane-hydrogen breath test, will be applied to investigate the mechanism of action from the perspectives of gut microecology, intestinal motility, and metabolism, so as to provide scientific evidence for the clinical application of rTMS in the treatment of IBS-D.",[28,512,513,514,515],"Irritable Bowel Syndrome With Diarrhea (IBS-D)","Repetitive Transcranial Magnetic Stimulation (rTMS)","Chronic Diarrhea","Intestinal Flora",[517,513],"Irritable Bowel Syndrome with diarrhea (IBS-D)",{"date":493,"type":38},{"date":520,"type":38},"2024-12-01",{"date":522,"type":21},"2026-07-01",{"name":524,"class":70},"The First Affiliated Hospital of Soochow University",{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":78,"minAge":17,"maxAge":228,"enrollmentInfo":532,"targetDuration":4,"studyType":22,"phases":534,"briefSummary":535,"conditions":536,"keywords":537,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":46},"100498950","phase-2-fecal-microbiota-transplantation-for-ibs-100498950","NCT05776914","Fecal Microbiota Transplantation for IBS","Efficacy and Safety of Proteolytic Activity-Guided Fecal Microbiota Transplantation for Irritable Bowel Syndrome (PRAGMAT Trial)","Inclusion Criteria:\n\n* IBS defined by Rome IV criteria\n* Non IBS-C\n* Moderate to severe symptoms defined by IBS-SSS≥175\n* Able to safely undergo and consent to colonoscopy\n\nExclusion Criteria\n\n* Immune deficiency or treatment with immunosuppressive medications\n* Severe bowel or medical disease precluding administration of bowel prep\n* Severe bowel or medical disease precluding colonoscopy with conscious sedation\n* Active cancer\n* Pregnant or lactating\n* Abdominal surgery (exception of splenectomy, partial hepatectomy, partial\u002Funilateral nephrectomy, laparoscopy, pelvic floor repair, mesh, liposuction, fundoplication, tubal ligation, gastric sleeve, oophorectomy, hernia, appendectomy, cholecystectomy, caesarean section and hysterectomy)\n* Severe psychiatric disorder (HADS-A or D\\>16), or diagnosed alcohol or drug abuse disorder\n* New probiotics or treatment with antibiotics, NSAIDs (within 4 wks prior to study entry)\n* Use of treatments known to affect colonic motility (with exception of loperamide)\n* Diagnosed h\u002Fo bleeding disorder\n* Organic GI diseases (IBD, celiac disease, microscopic colitis)\n* Chronic kidney or liver disease\n* Absolute neutrophil count (ANC) \\\u003C500 IU\u002Fml",{"count":533,"type":21},43,[140],"The purpose of this study is to learn the efficacy and safety of fecal microbiota transplantation (FMT) using stool from a donor with low proteolytic activity and containing the bacteria Alistipes putredinis in patients with irritable bowel syndrome (IBS) and high proteolytic activity. Proteolytic activity is the breakdown of proteins into smaller polypeptides or amino acids.",[28,167],[538,539],"Post-infection irritable bowel syndrome with diarrheal","Post-infection irritable bowel syndrome with mixed symptoms",{"date":541,"type":38},"2026-05-08",{"date":543,"type":38},"2024-04-15",{"date":545,"type":21},"2027-06-26",{"name":547,"class":70},"Madhusudan (Madhu) Grover, MBBS",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":78,"minAge":261,"maxAge":554,"enrollmentInfo":555,"targetDuration":4,"studyType":22,"phases":557,"briefSummary":558,"conditions":559,"keywords":560,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":567,"locationsCount":46},"100636027","effect-of-neurodynamic-mobilization-of-vagus-nerve-on-irritable-bowel-syndrome-in-women-100636027","NCT07560345","Effect of Neurodynamic Mobilization of Vagus Nerve on Irritable Bowel Syndrome in Women","Inclusion Criteria:\n\n* 32 Females with mild to moderate IBS ,were recruited for this study by referral from a physician.\n* aged 20-45 (i.e., the most common age for developing IBS)\n* Patients must experience abdominal pain recurring at least once weekly over the past three months.\n* This pain must be linked to two or more of the following features: occurring in relation to defecation, accompanied by a change in stool frequency, or accompanied by a change in stool form or appearance.\n* Symptoms should have been present during the last three months, with onset at least six months before diagnosis.\n\nExclusion Criteria:\n\nSubjects will be excluded if they have:\n\n* Organic gastrointestinal disorders.\n* Thyroid abnormalities.\n* Coexisting cardiovascular, respiratory, renal, or hepatic conditions.\n* Pregnancy.\n* Blood disorders. (e.g., hemophilia, coagulation disorders, leukemia, thalassemia, sickle cell disease).\n* Neurological or musculoskeletal conditions affecting muscle tone.\n* Psychiatric illnesses ( patients with depression in the absence of IBS).\n* Fibromyalgia.\n* A history of gastrointestinal surgery or resection, , or other chronic diseases associated with gastrointestinal issues such as inflammatory bowel disease, ulcers, or cancer.\n* A history of alcohol or drug abuse, abdominal surgery within the past six months.\n* Recent cervical or cardiac surgery, or recent major trauma.","45 Years",{"count":556,"type":21},32,[24],"goal of this interventional study to investigate the effect of neurodynamic mobilization of vagus nerve on irritable bowel syndrome in women. The main question it aims to answer is: is there an effect of neurodynamic mobilization of the vagus nerve on irritable bowel syndrome? The intervention will include neurodynamic mobilization of vagus nerve sessions ,Participants will receive the treatment for 6 week. Assessment will be done before and after treatment.",[28],[32],"2026-05-02",{"date":563,"type":38},"2026-05-07",{"date":565,"type":21},"2026-05-01",{"date":348,"type":21},{"name":98,"class":70},{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":574,"enrollmentInfo":575,"targetDuration":4,"studyType":22,"phases":576,"briefSummary":577,"conditions":578,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":582,"leadSponsor":584,"locationsCount":46},"100491564","feasibility-assessment-of-cardiovascular-endurance-training-for-the-symptomatic-improvement-of-irritable-bowel-syndrome-patients-with-a-sedentary-and-non-active-lifestyle-100491564","NCT05680766","Feasibility Assessment of Cardiovascular Endurance Training for the Symptomatic Improvement of Irritable Bowel Syndrome Patients With a Sedentary and Non-active Lifestyle.","Inclusion Criteria:\n\n* Patients aged 18 - 60 years;\n* Fulfilling the ROME IV criteria for Irritable bowel syndrome (IBS);\n* Moderate symptom severity as defined by a IBS-Symptom Severity Scale \\> 175;\n* Sedentary lifestyle defined as SIT-Q-7D \\> 8h\u002Fday;\n* Physically inactive defined as \\\u003C 150min\u002Fweek on the IPAQ score\n\nExclusion Criteria:\n\n* Cardiorespiratory disorder hampering participation in a program of physical exercise as evidenced by the sport + keuringsartsen (SKA) questionnaire.\n* Clinical suspicion of an organic disorder different from IBS (patients can be included when this disorder had been excluded);\n* Known inflammatory bowel disorder;\n* Known intestinal motility disorder;\n* Alcohol (defined as more than 14 U per week) or other substance abuse;\n* Active psychiatric disorder;\n* Known systemic or auto-immune disorder with implication for the GI system;\n* Prior abdominal surgery (with the exception of appendectomy or cholecystectomy more than 6 months ago);\n* Any prior diagnosis of cancer other than basocellular carcinoma;\n* Current chemotherapy;\n* History of gastro-enteritis in the past 8 weeks;\n* Change in diet in the past 8 weeks;\n* Dietary supplements unless taken at a stable dose for more than 8 weeks;\n* Antibiotics, pre-, pro-, post-biotics or any combination during the past 8 weeks;\n* Treatment with neuromodulators (one neuromodulator taken at a stable dose for more than 12 weeks is allowed);\n* Treatment with spasmolytic agents, opioids, loperamide, gelatine tannate or mucoprotect-ants during the past 8 weeks.","60 Years",{"count":285,"type":21},[24],"This exploratory study's primary objective is the changes of irritable bowel syndrome (IBS) symptom severity by cardiovascular endurance training (CET) in relation to the baseline sedentary or non-active lifestyle. Secondary endpoints focus on the mechanisms associated with these changes.\n\nThese mechanisms relate to dietary adaptations, changes in anxiety, depressive comorbidity, somatisation, alterations in the gut microbiome or metabolome, body composition and measures of cardiovascular fitness. Virtually all IBS guidelines mention lifestyle modifications as a management option.\n\nResearch on the role of physical activity remains underassessed as compared to the other interventions. Therefore, an exploratory proof-of-concept study will investigate the influence of regular physical exercise on symptoms in a small group of IBS patients. This study will gather data on putative underlying mechanisms related to dietary factors, faecal microbiome and metabolome, mental well-being, body composition and cardiovascular fitness.",[28],"2026-04-30",{"date":170,"type":38},{"date":40,"type":38},{"date":583,"type":21},"2030-01-02",{"name":585,"class":70},"Universitair Ziekenhuis Brussel",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":594,"conditions":595,"keywords":596,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":612,"leadSponsor":614,"locationsCount":46},"100634389","psychoemotional-status-and-functional-gastrointestinal-disorders-100634389","NCT07539051","Psychoemotional Status and Functional Gastrointestinal Disorders","Assessment of the Influence of Psychoemotional Status on the Clinical Course of Functional Disorders of the Stomach and Intestine","Inclusion Criteria:\n\n* Age 18 years and older\n* Diagnosis of irritable bowel syndrome and\u002For functional dyspepsia according to Rome IV criteria\n* Written informed consent for participation in the study\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Clinical presentation not meeting Rome IV criteria\n* Inflammatory bowel disease\n* Pregnancy or lactation\n* Malignant neoplasms of any localization\n* History of gastrointestinal surgery",{"count":54,"type":21},"This prospective cohort study will evaluate the influence of psychoemotional status on the clinical course and quality of life of adult patients with functional dyspepsia and\u002For irritable bowel syndrome diagnosed according to Rome IV criteria. The study aims to assess the contribution of affective and somatoform disorders to quality of life and symptom burden in these patients. In participants with functional dyspepsia, the association of Helicobacter pylori status with psychoemotional status and quality of life will also be evaluated. Patients will complete validated questionnaires assessing quality of life, depression, anxiety, and somatization at baseline and again during follow-up after treatment. Clinical symptoms, pain severity, stool characteristics, and H. pylori status will also be assessed as applicable.",[113,28],[597,89,598,599,600,601,602,603,604,605,606,607],"Psychoemotional Status","Anxiety","Depression","Somatization","PHQ-9","GAD-7","PHQ-15","SF-36","Helicobacter pylori","Rome IV","Gut-Brain Interaction","2026-04-13",{"date":610,"type":38},"2026-04-20",{"date":565,"type":21},{"date":613,"type":21},"2028-05-01",{"name":615,"class":70},"Center of New Medical Technologies",{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":620,"acronym":4,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":78,"minAge":261,"maxAge":622,"enrollmentInfo":623,"targetDuration":4,"studyType":22,"phases":625,"briefSummary":626,"conditions":627,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":632,"leadSponsor":634,"locationsCount":46},"100633962","effect-of-autogenic-relaxation-training-on-irritable-bowel-syndrome-in-adult-females-100633962","NCT07533500","Effect of Autogenic Relaxation Training on Irritable Bowel Syndrome In Adult Females","Inclusion Criteria:\n\n* Patients diagnosed with irritable bowel syndrome (IBS) based on Rome IV diagnostic criteria constipation- predominant IBS.\n\nTheir body mass index 25- 30.\n\nExclusion Criteria:\n\n* Organic gastrointestinal disorder, thyroid dysfunction, respiratory, renal, hepatic disorder.\n* Pregnancy, hematological disease, neurological and psychiatric disease.\n* Previous history of stomach or intestinal excision.","35 Years",{"count":624,"type":21},44,[24],"This study will be conducted to determine the effect of autogenic relaxation training on irritable bowel syndrome in adult females.",[28],"2026-04-10",{"date":630,"type":38},"2026-04-16",{"date":610,"type":21},{"date":633,"type":21},"2026-09-10",{"name":98,"class":70}]